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eparan sulfate (HS) interacts with diverse growth
factors, including Wnt, Hh, BMP, VEGF, EGF, and
FGF family members, and is a necessary component
for their signaling. These proteins regulate multiple cellular
processes that are critical during development. However, a
major question is whether developmental changes occur in
HS that regulate the activity of these factors. Using a ligand
and carbohydrate engagement assay, and focusing on FGF1
H
 
and FGF8b interactions with FGF receptor (FR)2c and FR3c,
this paper reveals global changes in HS expression in
mouse embryos during development that regulate FGF and
FR complex assembly. Furthermore, distinct HS requirements
are identiﬁed for both complex formation and signaling for
each FGF and FR pair. Overall, these results suggest that
changes in HS act as critical temporal regulators of growth
factor and morphogen signaling during embryogenesis.
 
Introduction
 
Heparan sulfate (HS) is a sulfated glycosaminoglycan ex-
pressed on core proteins at the cell surface and in the ECM
(Bernfield et al., 1999). HS modulates the activity of multiple
growth factor families, including FGFs, EGFs, VEGFs, and
HGF (Esko and Selleck, 2002). Similarly, HS also regulates
the activities of morphogens, including Wnts, Hh, and BMPs
(Nybakken and Perrimon, 2002). Because these morphogens
and growth factors are critical for embryogenesis, an important
question is whether developmental changes in HS regulate the
activities of these proteins. This is difficult to answer due to
technical problems with obtaining and analyzing HS from
discrete sites at specific developmental stages. Currently, only
gross analyses of overall HS sulfation levels in whole tissues are
possible (Safaiyan et al., 2000). These approaches fail to
identify the subtle differences in HS sulfation patterns thought
to regulate HS-binding proteins. Conversely, HS-specific anti-
bodies identify different HS epitopes (Dennissen et al., 2002),
but fail to demonstrate the functionality of these differences
with regard to growth factor and morphogen signaling.
In this paper, a ligand and carbohydrate engagement
(LACE) assay was used to map the ability of exogenous
growth factors and soluble growth factor receptors to interact
with HS in situ at different stages of embryogenesis. FGFs
were chosen for this analysis for several reasons. First, the
22 known FGFs regulate a multitude of developmental
processes including development of the limb, lung, heart,
and brain (Goldfarb, 1996). Second, although HS regulates
the activities of a number of different morphogens, this ability
is best understood for the FGFs (Ornitz, 2000). Studies using
cells deficient in HS first demonstrated a requirement of HS
in the formation of a high affinity FGF and FGF receptor (FR)
complex (Yayon et al., 1991), whereas studies using chemical
inhibitors of HS synthesis demonstrated a requirement for HS
in FGF signaling (Rapraeger et al., 1991). Third, studies have
shown that the requirement for HS represents an interaction
between not only FGFs and HS (Faham et al., 1996) but
also between FRs and HS (Kan et al., 1999). Finally, previous
work has identified tissue-specific differences in HS that
regulate the ability of both FGF and FGF–FR complexes to
interact with HS (Allen et al., 2001).
Because HS has been shown to undergo changes during
development (David et al., 1992; Jenniskens et al., 2002), the
goal of this paper is to determine whether such developmental
changes in HS might regulate morphogen signaling. To
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address this, LACE was performed using two FGFs: FGF1
and FGF8b, and two FRs: FR2c and FR3c. These FGFs and
FRs interact with one another, thus providing four different
pairs of probes for analysis. In addition, these FGFs and FRs
have been implicated in a number of developmental pro-
cesses, including heart formation (FGF1 and FGF8b), limb
development (FGF8b), and bone growth (FR2c and FR3c).
This paper identifies dramatic differences in the in situ
interactions of these four FGF-FR pairs with HS at differ-
ent developmental stages. In fact, for each FGF-FR pair ex-
amined, unique developmental HS binding patterns are
identified that correlate with different HS binding require-
ments, as well as differences in FGF signaling. These re-
sults suggest that each FGF-FR combination seeks distinct
HS domains that are spatially and temporally regulated
during development. These domains are unique to HS and
distinguish it from heparin, which is highly sulfated and
lacks any domain structure, thus explaining the ability of
these FGF-FR pairs to interact equally with heparin in
vitro. Importantly, the HS activity necessary for ternary
complex assembly does not represent the additive binding
requirements of individual FGFs or FRs; rather, it repre-
sents requirements dictated by the synergistic interaction
of the FGFs, HS, and FRs. Finally, given that HS uniquely
mediates each FGF–FR interaction examined here, these
results suggest that developmental changes in HS may also
specifically modulate the signaling of other families of
morphogens and growth factors.
 
Results
 
Characterization of HS-binding probes
 
FR2c and FR3c interactions with either FGF1 or FGF8b
were confirmed (Fig. 1 A) using a heparin-agarose bead
(HAB) binding assay where soluble chimeric proteins con-
sisting of the extracellular domain of either FR2c or FR3c
fused to alkaline phosphatase (FR2cAP and FR3cAP, respec-
tively) were incubated with HABs in either the presence or
absence of FGF1 or FGF8b (Ornitz et al., 1992; Allen et al.,
2001). Approximately 25% of FR2cAP and FR3cAP bind
HABs in the absence of FGF, confirming their affinity for
heparin (Kan et al., 1993); this binding is abolished by 500
mM NaCl washes. Incubation of FR2cAP with either FGF1
or FGF8b results in 
 
 
 
75% binding to HABs, even in 500
mM NaCl. Indeed, 2 M NaCl is required to abrogate ter-
nary complex assembly (unpublished data). In addition,
binding is specific, as it is blocked by soluble heparin.
FR3cAP also binds both FGF1-heparin and FGF8b-heparin
with high affinity (i.e., resistant to 500 mM NaCl washes),
although FR3cAP binds less well to FGF1-heparin (50%)
than to FGF8b-heparin (75%).
Activation of FR2c and FR3c signaling by either FGF1 or
FGF8b (Fig. 1 B) was examined using BaF3 cells, an IL-3 de-
pendent cell line normally negative for both FR and HS (Or-
nitz et al., 1996). Cells expressing FR2c die in the absence of
IL-3, or when supplemented with heparin or FGF1 alone,
but survive when treated with FGF1 and heparin. FR2c cells
respond equally well to FGF8b and heparin. FR3c expressing
cells behave similarly; they proliferate equally when treated
with heparin and either FGF1 or FGF8b.
 
Use of HS-binding probes to detect specific HS in situ
 
To question whether HS mediates these same interactions in
situ, LACE was performed on serial sections from mouse
embryos at different developmental stages (Allen et al.,
2001). Tissue sections from E18 mouse embryos were incu-
bated with either 100 nM FR2cAP or FR3cAP alone or with
30 nM exogenous FGF1 or FGF8b to assess binding to en-
dogenous HS. Varying the concentration of FGF from 3 to
100 nM or FR from 10 nM to 1 
 
 
 
M resulted in identical
staining patterns, although of different intensities. Use of
lower concentrations resulted in a significant loss of signal,
whereas incubation with 
 
 
 
100 nM FGF or 1 
 
 
 
M FR1cAP
led to nonspecific (i.e., HS independent) binding to sec-
tions. Bound FR–alkaline phosphatase (FRAP) was detected
using antibodies against its AP portion. The initial focus was
in the developing heart and lung because previous work has
shown that HS from these two tissues differentially mediates
FGF4 and FR interactions (Allen et al., 2001).
HS is identified throughout the embryo (Fig. 2 A) using
mAb 3G10, which recognizes the unsaturated uronic acid
residue of HS remaining on the core protein after heparin-
ase III digestion. In contrast to their affinity for heparin,
neither FR2cAP nor FR3cAP bind to HS in this region
(Fig. 2, B and F) or elsewhere in the embryo (unpublished
data). This is surprising, because FRs do have an affinity for
HS by themselves (Powell et al., 2002). Importantly, FRAP
incubation at concentrations as high as 1 
 
 
 
M still results
in a failure to bind to HS (unpublished data). However,
FRAP incubation together with FGF does result in bind-
ing to HS. FR2cAP recognizes FGF1–HS complexes in
the heart/lung (Fig. 2 C), representative of binding seen
throughout the E18 mouse embryo, indicating that FR2c
and FGF1 recognize and interact with HS at these sites.
Figure 1. Binding and activation of FR2c and FR3c by FGF1-heparin 
and FGF8b-heparin. (A) Percent FRAP binding to HABs under the 
conditions shown. (B) Numbers of BaF3 cells expressing either FR2c 
or FR3c after 48 h in culture medium with the indicated treatments.T
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FR2cAP and FGF8b also interact with HS throughout the
E18 embryo (Fig. 2 D). As with FR2cAP, FR3cAP also rec-
ognizes FGF1-HS (Fig. 2 G) and FGF8b-HS (Fig. 2 H) in
the heart and lung, as well as throughout the E18 mouse
embryo. As a control for specificity, all binding is abolished
if the section is pretreated with a combination of HS lyases
(Fig. 2 E); lyase removal of HS blocks binding of any com-
bination of FGF and FRAP described in this paper (unpub-
lished data). In total, these results suggest that HS is capa-
ble of mediating complex formation between either FR2c
or FR3c and FGF1 or FGF8b.
Although there is no apparent difference in the binding of
either receptor to FGF1 or FGF8b in E18 embryos, differ-
ences in HS at earlier developmental stages might affect FGF
and FR complex assembly. To test this, LACE was per-
formed on sections from E8.5 mouse embryos. Indeed, al-
though FR2cAP recognizes FGF1-HS throughout the em-
bryo at the E8.5 stage (Fig. 2 K), this FR fails to interact with
FGF8b-HS at any sites (Fig. 2 L). In contrast, FR3cAP binds
throughout the embryo in the presence of either FGF1 (Fig.
2 O) or FGF8b (Fig. 2 P). Again, both FRs fail to bind in the
absence of FGF (Fig. 2, J and N) and binding is abolished by
HS lyases (Fig. 2 M). Thus, HS from E8.5 embryos mediates
the formation of a high affinity complex of FR3cAP with ei-
ther FGF1 or FGF8b, and FR2cAP with FGF1, but fails to
mediate association of FR2cAP and FGF8b.
To determine whether HS from other stage embryos
might have yet a different activity, LACE was performed
on E9.5 embryos. Here, HS mediates the interactions of
FR2cAP with FGF1 (Fig. 3 C), and in contrast to E8.5 em-
bryos, HS also mediates FR2cAP interactions with FGF8b
(Fig. 3 D). Perhaps most striking is the global change;
HS fails to mediate FGF8b–FR2cAP interactions in E8.5
embryos, but does mediate FGF8b–FR2cAP interactions
throughout E9.5 embryos. Global changes in HS also affect
FR3cAP interactions in these embryos. FR3cAP fails to rec-
ognize FGF1-HS except weakly in certain basement mem-
branes near the surface ectoderm (Fig. 3 G), opposite to that
seen in E8.5 embryos, where FR3cAP binds FGF1-HS at all
sites. However, FR3cAP binds FGF8b-HS throughout E9.5
embryos (Fig. 3 H).
LACE was also used 2 d later in E12 embryos. FR2cAP
binds FGF1-HS throughout the embryo (Fig. 3 K). In con-
trast, it fails to bind FGF8b-HS in the majority of the em-
bryo (Fig. 3 L), similar to its binding profile at E8.5.
FR2cAP does bind FGF8b–HS complexes weakly in select
basement membranes surrounding the brain and spinal cord
as well as in the surface ectoderm. A potential explanation
for this failure is a lack of FGF8b binding to HS. However,
FR3cAP does bind FGF8b-HS throughout the E12 embryos
(Fig. 3 P). Thus, FGF8b interacts with HS in E12 embryos,
at least when in a ternary complex with FR3cAP. Examina-
tion of FR3cAP binding to FGF1-HS in these embryos re-
veals a more tissue-specific HS binding pattern (Fig. 3 O).
The FR binds FGF1-HS in multiple sites, including the
liver, neuroepithelium, and the branchial arch. However,
FR3cAP fails to bind FGF1-HS in either the atrium or the
ventricle of the heart. FR3cAP also binds FGF1-HS less
strongly in the somites, although there is some experimental
variation in this staining.
 
Each FGF-FR pair seeks a distinct HS domain
 
In total, these results suggest that developmental stage–spe-
cific changes in HS regulate FR2cAP and FR3cAP complex
assembly with either FGF1 or FGF8b, apparently due to
changes in the structure of HS. Furthermore, these data sug-
gest that each FR and FGF pair seeks a different HS domain,
even though this was not initially observed at the E18 stage.
To test whether the FGF-FR pairs are indeed binding to dif-
ferent HS domains in E18 embryos, selectively desulfated
heparins were used to compete binding to endogenous HS
at this stage. The results focus on the lung, although similar
binding is seen throughout the embryo. Sections were prein-
cubated with FGF, creating preformed FGF–HS complexes
on the section, followed by FRAP alone, or in the presence
of heparin, 2-
 
O
 
-desulfated (2-ODS) heparin, or 6-ODS
heparin (Fig. 4). When FR2cAP is incubated with sections
Figure 2. FGF8b and FR2cAP assemble with E18 HS, but not E8.5 
HS. (A–H) Composite pictures of serial sagittal sections of E18 heart 
(atrium, At; and ventricle, Ve); lung (Lu), diaphragm (Di), and liver 
(Li) are shown. (I–P) Sagittal sections of E8.5 mouse embryos are 
shown as composite images (H, head; He, heart; and T, tail). 
(A and I) Total HS distribution is identified by mAb 3G10 after 
treatment with heparin lyases. Sections are incubated with either 
(B and J) 100 nM FR2cAP or (F and N) 100 nM FR3cAP alone or in 
the presence of (C, G, K, and O) 30 nM FGF1 or (D, H, L, and P) 
30 nM FGF8b. (E and M) FR3cAP is also incubated in the presence of 
FGF8b on sections pretreated with heparin lyases. FRAP is visualized 
with antibody to AP. Each treatment was repeated at least three times 
using different embryos for both stages of development. Bars, 500  m.T
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treated previously with FGF8b, the FR binds avidly to the
FGF8b–HS complexes in the lung (Fig. 4 A). However, in-
cubation of FR2cAP together with heparin blocks the bind-
ing, suggesting that the heparin may compete by occupying
the heparin-binding domain (HBD) on the FR (Fig. 4 B).
Incubation of FR2cAP with either 2-ODS heparin (Fig. 4
C) or 6-ODS heparin (Fig. 4 D), results in no competition.
This tentatively suggested that FR2cAP does not interact
with heparin that lacks either 2-
 
O
 
-sulfation or 6-
 
O
 
-sulfa-
tion. Turning to FR3cAP, this FR also binds strongly to
FGF8b-HS in the lung (Fig. 4 E). Again, incubation of
FR3cAP with heparin results in competition of binding of
FR3cAP to the section (Fig. 4 F). Interestingly, incubation
of FR3cAP with 2-ODS heparin also competes binding
(Fig. 4 G), whereas it does not compete FR2cAP. However,
like FR2cAP, FR3cAP binding to FGF8b-HS is not com-
peted by 6-ODS heparin (Fig. 4 H). These results tenta-
tively suggested that FR3cAP does not require 2-
 
O
 
-sulfation
in order to interact with heparin, but does require 6-
 
O
 
-sulfa-
tion. Overall these results indicate that these FR and FGF
pairs do require different sulfation patterns for their interac-
tion, and tentatively suggest specificities of the FR HBDs.
To confirm that this competition identifies differences
in the FR HBDs, heparin competition of FRAP binding to
FGF1-HS was examined. Here, the competition with FR
binding to FGF1 would be expected to be identical to
FGF8b if only the FR is being competed by the modified
heparin. As expected, FR2cAP and FR3cAP both bind
Figure 3. Global changes in HS-medi-
ated assembly of FGF1-FR3cAP and 
FGF8b–FR2cAP complexes in E9.5 and 
E12 mouse embryos. Composite images 
of sagittal sections of (A–H) E9.5 and 
(I–P) E12 embryos are shown. Detection 
of (A and I) total HS with mAb 3G10; 
(B and J) binding of 100 nM FR2cAP 
alone; (C and K) binding of FR2cAP in the 
presence of 30 nM FGF1 or (D and L) 
30 nM FGF8b; (F and N) 100 nM FR3cAP 
alone; (G and O) binding of FR3cAP in 
the presence of 30 nM FGF1 or (H and P) 
30 nM FGF8b. (E and M) Sections pre-
treated with heparin lyases and incubated 
with 100 nM FR3cAP and 30 nM FGF8b. 
He, heart; Li, liver; BA, branchial arch; 
and Ne, neuroepithelium. Experiments 
were repeated at least three times with 
different embryos to confirm the results. 
Bars, 500  m.
Figure 4. Heparin competition of FGF–FRAP complexes from HS 
in E18 mouse embryos. Detection of FR2cAP (A–D and I–L) or 
FR3cAP (E–H and M–P) binding to E18 lung preincubated with (I–P) 
30 nM FGF1 or (A–H) 30 nM FGF8b. Incubation of (A, E, I, and M) 
100 nM FRAP alone, or with (B, F, J, and N) 50 nM heparin, (C, G, 
K, and O) 50 nM 2-ODS heparin, or (D, H, L, and P) 50 nM 6-ODS 
heparin. Bar, 100  m.T
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FGF1-HS (Fig. 4, I and M), and binding of both FRAPs is
competed with heparin (Fig. 4, J and N). Surprisingly, nei-
ther FR2cAP nor FR3cAP binding is competed with either
2-ODS heparin (Fig. 4, K and O) or 6-ODS heparin (Fig.
4, L and P), suggesting that 2-
 
O
 
-sulfates and 6-
 
O
 
-sulfates
are necessary for both FR2c and FR3c assembly with
FGF1. This contrasts with FGF8b, where 2-
 
O
 
-sulfates ap-
pear unnecessary for binding to FR3c. This unexpected
finding suggests that the HS binding requirements of spe-
cific FRs alone are not being tested. One explanation is
that the heparin competes FGF binding to sections. How-
ever, for this to be true, 2-ODS heparin should compete
both FR2cAP and FR3cAP binding to FGF8b-HS, which
it does not. Another possibility is that these heparins selec-
tively compete by inserting into a binding pocket gener-
ated only when the FGF and FR are assembling into a
complex. This possibility is consistent with the data, and
was examined further.
To test FR3cAP and FGF8b interactions in the absence of
2-
 
O
 
-sulfates, complex assembly with HS from mouse em-
bryos that lack 2-
 
O
 
-sulfation was examined using LACE.
Mice expressing a gene trap mutation in 
 
Hs2st
 
 do not ex-
Figure 5. FGF8b and FR3c form an active signal-
ing complex in the absence of 2-O-sulfation. As-
sembly of FGF–HS–FRAP complexes on (A–D) E10 
Hs2st
 /  and (E–H) Hs2st
 /  embryos and wild-
type (I–L) CHO-K1 and (M–P) pgsF-17 cells. mAb 
3G10 identification of total HS (A, E, I, and M). 
Binding of (B, F, J, and N) 100 nM FR3cAP after in-
cubation alone, or with (D, H, L, and P) 30 nM 
FGF8b. Binding of 100 nM FR2cAP after incuba-
tion with (C, G, K, and O) 30 nM FGF8b. Bar, 100 
 m. (Q) Quantification of BaF3 cells expressing ei-
ther FR2c or FR3c after 48 h in the treatments 
shown. (R) Proliferative response of BaF3 cells ex-
pressing FR3c to FGF1 or FGF8b and HS isolated 
from either CHO-K1 or pgsF-17 cells. (Q and R) Er-
ror bars represent the SD for quadruplicate sam-
ples in a single experiment, and are representative 
of three independent experiments.T
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press HS 2-
 
O
 
-sulfotransferase (HS2ST) and synthesize HS
lacking 2-
 
O
 
-sulfation (Bullock et al., 1998). FR2cAP and
FR3cAP binding to FGF8b-HS in tissue sections from both
 
Hs2st
 
 
 
/
 
 
 
 and 
 
Hs2st
 
 
 
/
 
 
 
 E10 embryos from the same litter was
examined. This focused on the primitive ventricle of the
heart. Although FR2cAP interacts with FGF8b-HS in the
 
Hs2st
 
 
 
/
 
 
 
 embryos (Fig. 5 C), it fails to bind FGF8b-HS in
the 
 
Hs2st
 
 
 
/
 
 
 
 embryos (Fig. 5 G). In contrast, FR3cAP inter-
acts with FGF8b-HS in both the 
 
Hs2st
 
 
 
/
 
 
 
 (Fig. 5 D) and
 
Hs2st
 
 
 
/
 
 
 
 (Fig. 5 H) embryos. Thus, FR3cAP and FGF8b
form a ternary complex with HS that lacks 2-
 
O
 
-sulfation,
but FR2cAP and FGF8b cannot.
These results were extended using CHO cells that also fail
to express HS2ST (pgsF-17 cells; Bai and Esko, 1996). As in
the 
 
Hs2st
 
 embryos, FR2cAP bound to FGF8b-HS on wild-
type CHO-K1 cells (Fig. 5 K), but failed to bind FGF8b-
HS on 2-
 
O
 
-sulfate deficient pgsF-17 cells (Fig. 5 O).
FR3cAP binding on these cells was also equivalent to that
seen in the 
 
Hs2st
 
 embryos, interacting with FGF8b-HS on
both CHO-K1 cells (Fig. 5 L) and pgsF-17 cells (Fig. 5 P).
To confirm that LACE accurately depicts interactions nec-
essary to form an active signaling complex, the proliferative
response of BaF3 cells expressing either FR2c or FR3c was
examined (Fig. 5 Q). As expected from LACE, FR2c cells do
not respond to FGF-8b in the presence of either 2-ODS
heparin or 6-ODS heparin. Thus, FGF8b-FR2c requires
heparin or HS containing both 2-
 
O
 
-sulfation and 6-
 
O
 
-sulfa-
tion to form an active signaling complex. FR3c cells also fail
to respond to FGF8b and 6-ODS heparin. However, they
do respond to FGF8b and 2-ODS heparin. This confirms
that although FGF8b-FR3c requires heparin bearing 6-
 
O
 
-
sulfates to assemble and signal, 2-
 
O
 
-sulfation is not neces-
sary. The response of FR2c and FR3c cells to FGF1 was ex-
amined next (Fig. 5 Q). Neither cell line responds to FGF1
in combination with either 2-ODS heparin or 6-ODS
heparin.
To directly correlate the formation of FGF–HS–FR com-
plexes on cells and sections with the formation of an active
signaling complex, HS was also isolated from both CHO-
K1 and pgsF-17 cells for use in proliferation assays (Fig. 5
R). FR3c cells respond to either FGF1 or FGF8b with HS
from CHO-K1 cells. In contrast, FR3c cells respond to
FGF8b with HS from pgsF-17 cells, but fail to respond to
FGF1 with this HS. Importantly, these results correspond
exactly to the formation of ternary complexes of FGF–HS–
FR on fixed monolayers of these cells.
 
FGF-FR pairs interact synergistically to identify 
an HS domain
 
There are three potential explanations for the failure of
FGF1 to assemble with either FR2c or FR3c and HS in the
absence of 2-
 
O
 
-sulfation or 6-
 
O
 
-sulfation. The first is that
FGF1 requires 2-
 
O
 
-sulfates and 6-
 
O
 
-sulfates in order to
bind HS; this is consistent with previously published results
(Guimond et al., 1993; Kreuger et al., 2001). A second ex-
planation is that both FRs require 2-
 
O
 
-sulfates and 6-
 
O
 
-sul-
fates in order to bind HS; however, this is inconsistent with
the results using FGF8b described previously (Figs. 4 and 5).
A third explanation is that formation of the ternary complex
uses sulfation requirements not exhibited by either the FGF
or the FR binding individually.
To test whether the 2-
 
O
 
-sulfation requirement for FRAP
binding to FGF1 reflects a requirement of the FGF alone,
the FR alone, or a requirement unique to this ternary com-
plex, the binding of FR2cAP, FR2bAP, and FR3cAP to
FGF1 was examined (Fig. 6). Here, FR2b and FR2c were
compared because these two splice variants of FR2 both rec-
ognize FGF1 and have identical HBDs because splicing does
not alter the amino acid sequence in this region of DII. A re-
cent paper also indicates that FGF1 signals through FR2b in
the absence of either 2-
 
O
 
-sulfation or 6-
 
O
 
-sulfation (Ostro-
vsky et al., 2002). Binding was examined using the 
 
Hs2st
 
embryos as well as the pgsF-17 cells. In 
 
Hs2st
 
 
 
/
 
 
 
 and 
 
Hs2st
 
 
 
/
 
 
 
embryos, FR2bAP fails to bind in the absence of FGF1
(Fig. 6, A and E), but does assemble with FGF1 and HS ex-
pressed by either the 
 
Hs2st
 
 
 
/
 
 
 
 or the 
 
Hs2st
 
 
 
/
 
 
 
 embryos (Fig.
6, B and F); thus, both FR2b and FGF1 in this complex in-
teract with HS that lacks 2-
 
O
 
-sulfates. In contrast, FR2cAP
and FR3cAP both fail to bind FGF1-HS in the 
 
Hs2st
 
 
 
/
 
 
 
embryos (Fig. 6, G and H), although they do bind FGF1-
HS in the 
 
Hs2st
 
 
 
/
 
 
 
 embryos (Fig. 6, C and D). This result is
confirmed using CHO-K1 cells or 2-
 
O
 
-sulfate deficient
pgsF-17 CHO cells (Fig. 6, I–R). In addition, FGF1 bind-
ing to HS in either cell type was directly examined using
an FGF1-specific antibody. Although FGF1 binds HS in
CHO-K1 cells (Fig. 6 I), it fails to bind in the pgsF-17 cells
(Fig. 6 N). FGF1 does bind pgsF-17 HS, however, when in-
cubated simultaneously with FR2bAP (Fig. 6 P, inset).
To confirm that FR2bAP and FGF1 interact in the ab-
sence of 2-
 
O
 
-sulfation, the ability of 2-ODS heparin to
compete FGF1 and FR2bAP binding to HS was examined
(Fig. 6, S–V). FR2bAP and FGF1 assemble with lung HS in
E18 embryos (Fig. 6 S), but binding is abrogated when in-
cubated with heparin (Fig. 6 T). In addition, binding is also
abrogated when FGF1 and FR2bAP are incubated with ei-
ther 2-ODS heparin (Fig. 6 U) or 6-ODS heparin (Fig. 6
V). To correlate binding with activity, the response of BaF3
cells expressing FR2b was examined in response to treatment
with FGF1 and heparin, 2-ODS heparin, or 6-ODS heparin
(Fig. 6 W). These data show that FR2b cells respond to
FGF1 with any of the heparins used. Overall, these data sup-
port the third explanation advanced earlier, namely, that ter-
nary complex formation invokes binding requirements dis-
tinct from the FGF or the FRAP HBDs alone. Therefore,
although an FGF and FR may separately have identifiable
HS binding requirements, the HS requirements necessary to
simultaneously form a ternary complex may be different.
FR2bAP and FR2cAP interactions with FGF1 were fur-
ther examined with HS that lacks 2-
 
O
 
-sulfation by preincu-
bating the FGF alone with the HS, followed by washing be-
fore addition of the FRAP (Fig. 7). HS clearly retains FGF1
and this FGF–HS complex assembles with either FR2cAP or
FR2bAP in the 
 
Hs2st
 
 
 
/
 
 
 
 embryos (Fig. 7, A and B). How-
ever, no assembly is detected in the 
 
Hs2st
 
 
 
/
 
 
 
 embryos (Fig. 7,
D and E). Identical results were observed in wild-type (Fig.
7, G and H) and pgsF-17 CHO cells (Fig. 7, J and K). This
suggests that FGF1 does require 2-
 
O
 
-sulfation in order to
bind HS with appreciable affinity by itself. However, this re-
quirement does not exist if FGF1 assembles with certainT
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FRs, such as FR2b where a ternary complex forms in the ab-
sence of 2-
 
O
 
-sulfation. Interestingly, FR3cAP interacts with
preincubated FGF8b-HS in both the 
 
Hs2st
 
 
 
/
 
 
 
 (Fig. 7 C) and
 
Hs2st
 
 
 
/
 
 
 
 embryos (Fig. 7 F), as well as in the wild-type (Fig.
7 I) and pgsF-17 CHO cells (Fig. 7 L). Thus, FGF8b does
not require 2-
 
O
 
-sulfation to bind HS independent of an FR.
 
Discussion
 
Identification of developmental stage–specific HS
 
The focus of this paper was to examine whether HS regulates
ligand–receptor interactions in a developmental stage–specific
manner. LACE was used with four different sets of FGF-FR
probes to survey the developing mouse embryo at various ges-
tational stages. Although the FGF-FR pairs interact with hep-
arin in vitro, and with HS in vivo in E18 stage embryos,
dramatic differences are seen at several earlier stages of devel-
opment (E8.5, E9.5, and E12). Importantly, each FGF-FR
pair examined has unique HS-binding requirements, which
suggest that within HS there are distinct domains that act as
highly specific regulators of morphogen signaling.
These results provide an important insight into HS regula-
tion of FGF signaling and potentially that of other HS-
dependent morphogens. Specifically, LACE now provides an
ability to assess HS in developmental processes where expres-
sion of FGFs and FRs are known, but the activity of the HS,
a critical regulatory partner in these signaling interactions, is
unknown. One such process is heart development, where
both FGF1 and FGF8b play important roles. FGF1 (as well
as FGF2 and FGF4) impacts the differentiation of chick pre-
cardiac mesenchyme and also appears later (stages 18–24)
during chick heart chamber development (Zhu et al., 1996),
which corresponds with E9–11 in the mouse. FGF8 affects
the induction of cardiogenic precursors during both zebrafish
and chick heart development (Reifers et al., 2000; Alsan and
Schultheiss, 2002). FGF8 also regulates the establishment of
left–right asymmetry in the developing mouse heart (Meyers
and Martin, 1999). In addition, there are reports that the in-
Figure 6. FGF1–FR2bAP complex assembly in the absence of 2-O-sulfation. Assembly of FGF–HS–FRAP complexes on (A–D) E10 Hs2st
 /  
and (E–H) Hs2st
 /  embryos and wild-type (I–M) CHO-K1 and (N–R) pgsF-17 cells. Detection of FRAP after binding of (A, E, J, and O) 100 nM 
FR2bAP alone or (B, F, K, and P) 100 nM FR2bAP, (C, G, L, and Q) 100 nM FR2cAP, or (D, H, M, and R) 100 nM FR3cAP in the presence of 
30 nM FGF1. FGF1 binding alone (I and N) or in the presence of FR2b (K and P, insets) or FR2c (L and Q, insets) is detected. Formation of 
FGF1 and FR2bAP complexes is detected in (S) E18 mouse lung alone or in the presence of (T) 50 nM heparin, (U) 50 nM 2-ODS heparin, or 
(V) 50 nM 6-ODS heparin. (W) The proliferative response of BaF3 cells expressing FR2b to FGF1 and heparin, 2-ODS heparin, or 6-ODS 
heparin is measured. Bar, 100  m. Error bars represent the SD for quadruplicate samples in a single experiment, and are representative of 
three independent experiments.T
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hibition of proteoglycan synthesis disrupts heart develop-
ment (Walsh and Stainier, 2001) and left–right asymmetry
in the heart (Yost, 1992). This corresponds with our current
and prior work (Allen et al., 2001), which suggests that HS
in the developing heart displays a high degree of specificity in
mediating FGF and FR interactions. In particular, the inabil-
ity of FGF1 and FR3c to interact in E12 mouse heart com-
pared with restored binding of this FGF-FR pair in E9.5
mouse heart suggests that HS may specifically regulate FGF1
signaling in the heart at different developmental stages.
A second process that requires FGF signaling is limb devel-
opment. Specifically, FGF8b is expressed in the apical ectoder-
mal ridge at E9-E12.5 (Crossley and Martin, 1995) and tar-
geted inactivation of FGF-8 in the mouse clearly demonstrates
that FGF8 is essential for normal limb development (Sun et
al., 2002). However, an important issue that remains is the
identification of the FR through which FGF8 signals in the
limb. Inactivation of the Fgfr2 gene results in the loss of limb
formation in the mouse (Arman et al., 1999), although recent
evidence demonstrates that the limb phenotype resulting from
inactivation of Fgfr2 targets FR2b and not FR2c (Revest et al.,
2001; Eswarakumar et al., 2002). Genetic studies suggest that
FR1c is important for limb development (Deng et al., 1997),
although it is not likely that FGF8 can signal through this re-
ceptor because activity studies have shown that micromolar
concentrations of FGF8b are needed to transduce a signal
through FR1c (MacArthur et al., 1995). Further studies will
be necessary to identify the FR through which FGF-8b signals
during limb development, but the data in this paper suggest
that, if FGF8b and FR2c do interact in the limb, there is a
specific developmental window during which the HS is appro-
priate, namely, at E9.5 stage of development.
FGF signaling also regulates brain development (Dono,
2003). Both FGF1 and FGF8, as well as FR2c and FR3c are
expressed in a tissue-specific and developmental stage–spe-
cific manner during brain development (Peters et al., 1993;
Reid and Ferretti, 2003). Although the role of FGF1 expres-
sion in the brain remains unclear, data suggest that FGF8 is
critical for correct patterning of the neocortex (Fukuchi-Shi-
mogori and Grove, 2001), as well as cell survival in the devel-
oping forebrain and midbrain (Chi et al., 2003). In addition,
FR3 may be important for postnatal brain development, par-
ticularly for the terminal differentiation of oligodendrocytes
(Oh et al., 2003). Our data suggest that FGF8 and FR3c are
able to signal throughout the brain during development, but
that FGF8 signaling through FR2c, as well as FGF1 signaling
through both FR2c and FR3c, is restricted by the expression
of developmental stage–specific HS in the brain.
However, perhaps the most striking finding is not just the
existence of these developmental changes but also the global
manner in which they occur. That is, HS changes through-
out the entire embryo. This is not necessarily surprising in a
physical sense, because the embryo is undergoing tremen-
dous growth and remodeling at these stages. However, it is
surprising that the synthesis of specific HS domains is
tightly and uniformly regulated throughout all embryonic
tissues. Importantly, the expression of HS biosynthetic en-
zymes does change during development (Aikawa et al.,
2001; Ford-Perriss et al., 2002), as does the expression of
core proteins to which HS is attached (Kim et al., 1994; Lit-
wack et al., 1998). However, these findings focus on indi-
vidual tissues and provide no indication that such changes
are global. Extracellular sulfatases, which act to modify HS
already present at the cell surface or in the ECM are also re-
ported (Dhoot et al., 2001; Morimoto-Tomita et al., 2002);
however, these also appear localized in their expression.
Thus, although changes in the expression of enzymes or core
proteins may suffice to explain tissue-specific changes in HS
structure, none of them appears adequate to explain the glo-
bal changes in HS structure shown here. Whatever the ex-
planation, it appears to be a highly coordinated regulation
that encompasses all of the tissues in the embryo.
Figure 7. FGF1 fails to bind HS in the absence of 2-O-
sulfation. Sections are from (A–C) E10 Hs2st
 /  or (D–F) 
Hs2st
 /  embryos or fixed (G–I) CHO-K1 or (J–L) pgsF-17 
cells. Binding of (A, D, G, and J) FR2bAP or (B, E, H, and K) 
FR2cAP to sections or cells preincubated with 30 nM FGF1 
is shown. Bound FR3cAP is detected after incubation of 
100 nM FR3cAP on sections or cells preincubated with 
(C, F, I, and L) 30 nM FGF8b. Bar, 100  m.T
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HS requirements for FGF–FR complex assembly 
and signaling
Because HS-mediated FGF–FR complex assembly varies
with each developmental stage, a major objective of this pa-
per was to identify the HS requirements that determine
these interactions. Strikingly, individual FGF-FR pairs ex-
hibit unique HS binding requirements for ternary complex
assembly. In fact, no two FGF-FR pairs display the same
combination of (a) HS-binding patterns in developing em-
bryos and (b) sulfation requirements necessary for ternary
complex assembly and signaling (Table I). Importantly, the
binding requirement of the FR changes depending on the
identity of the FGF, even between FR2b or FR2c; two splice
variants of the same FR gene product in which the HBD is
presumably identical. This suggests that the HS-binding
pocket displayed by an FGF-FR pair is unique to that pair
and may or may not reflect the binding properties of either
protein alone. Perhaps the interaction of the FR and FGF
exposes or masks amino acids that contribute to HS binding
in either protein. This may be a physical masking produced
by the protein–protein interaction, or it might involve slight
conformational changes in the proteins. In fact, a recent
crystallographic study demonstrates that FR2b does indeed
undergo a conformational change upon binding to FGF10
(Yeh et al., 2003).
Role of 2-O-sulfation in FGF signaling
The interactions of FGF8b–FR3c and FGF1–FR2b with
HS lacking 2-O-sulfation provide insight into other works.
First, the phenotypic effects of the Hs2st gene knockout in
mice (Bullock et al., 1998), are relatively mild given the im-
portant role of FGF signaling during development, and the
reliance of FGF signaling on HS. However, it is now clear
that 2-O-sulfation is dispensable for at least two FGF–FR
interactions, and possibly more. Of course, these mice also
show an increase in both N- and 6-O-sulfation, suggesting a
potential mechanism that compensates for the loss of 2-O-
sulfation (Merry et al., 2001). Nonetheless, our data show
that FGF1 and FR2c are unlikely to interact in these mice.
A second insight is provided by the assembly of FGF1 and
FR2b with HS in the absence of 2-O-sulfation. Conflicting
reports exist in the literature, showing that FGF1 requires
2-O-sulfation to bind HS and signal through an FR (Gui-
mond et al., 1993; Kreuger et al., 2001), or showing that
FGF1 can signal through FR2b in the absence of 2-O-sulfa-
tion (Ostrovsky et al., 2002). Our data provide an explana-
tion for the apparent discrepancy, namely, that FGF1 by it-
self does require 2-O-sulfation to interact with HS, as well as
to interact in a complex with HS and FR2c, but does not re-
quire 2-O-sulfation to interact in a complex with HS and
FR2b. In other words, the binding requirements of FGF1
alone or for its signaling through one FR do not suffice to
predict its signaling requirements with another FR. Impor-
tantly, a recent paper demonstrates that FGF1 and FR1c
display similar HS binding requirements (Wu et al., 2003).
Proposed model of FGF–HS–FR complex assembly
Based on the insights that this paper provides into the physi-
cal assembly of an FGF–HS–FR complex, we propose two
related models for the formation of a high affinity FGF–
HS–FR complex. In the first model, specific HS domains
exist that contain the appropriate sulfation pattern necessary
for FR recognition. This is based on the data presented in
this paper, as well as the work of other labs, which have
shown that FRs appear to specifically recognize different HS
domains (Guimond and Turnbull, 1999; Powell et al.,
2002). There are also specific HS domains that are selec-
tively recognized by FGFs. However, ternary complex for-
mation occurs only when an HS domain contains the sulfa-
tion pattern necessary for both FGF and FR recognition. In
this model (additive), the HS domain is simply a sum of the
individual FGF and FR binding requirements. In the second
model (synergistic), there are again FGF and FR-specific HS
domains, which are selectively recognized by one compo-
nent independently of the other. However, the HS domain
that mediates ternary complex formation contains a differ-
ent set of sulfation requirements that is dictated by the bind-
ing pocket formed by specific FGF-FR pairs. It is this syner-
gistic model that fits the data presented for the FGF1–FR2b
interactions. However, for FGF8b, either model could be
true, given the data available. Therefore, more experiments
will be required to determine if the synergistic model pre-
sented here is a general feature of all FGF–FR interactions,
or if it is specific to FGF1.
HS regulation of growth factor signaling
Published reports from this lab and others have demon-
strated the usefulness of LACE to elucidate tissue-specific
Table I. FGF-FR pairs display unique combinations of developmental HS-binding patterns and sulfation requirements
Developmental stage Sulfation requirement
a
FGF-FR pair E8.5 E9.5 E12 E18 2-O-sulfation 6-O-sulfation
FGF1-FR2b ND ND ND ND   
FGF1-FR2c          
FGF1-FR3c     
b     
FGF8b-FR2c          
FGF8b-FR3c          
ND, no data.
aSulfation requirements are based on FGF–FR complex assembly and signaling with heparin or HS that lacks either 2-O-sulfation or 6-O-sulfation. No data
are available regarding FGF-FR signaling in the absence of both 2-O-sulfation and 6-O-sulfation. Thus, although FGF1-FR2b interact in the absence of
either 2-O-sulfation or 6-O-sulfation, it is unknown if complex assembly occurs with the simultaneous loss of both 2-O-sulfation and 6-O-sulfation.
bFGF1-FR3c interact at multiple sites in E12 mouse embryos, but fail to interact in the heart, and interact only weakly in somites.T
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interactions between FGFs, FRs, and HS (Chang et al.,
2000; Allen et al., 2001), as well as between other ligands
and carbohydrates (Desnoyers et al., 2001; Rubin et al.,
2002). This paper now also demonstrates the utility of
LACE to identify developmental stage–specific HS do-
mains that regulate ligand–receptor interactions. The
identification of these domains also suggests that, given
the multitude of morphogen interactions mediated by HS,
developmental stage–specific changes in HS may also af-
fect the functions of these proteins. Studies in Drosophila
melanogaster have demonstrated that HS regulates the
function of a number of developmental signaling mole-
cules, including Hh, Wg, and Dpp (Nybakken and Perri-
mon, 2002). Importantly, HS may not only regulate
ligand–receptor interactions, as described here for FGF
signaling, but may also regulate morphogen gradient for-
mation during development. Data from other laboratories
have shown that alterations in HS have dramatic effects
on the accumulation of Wg during development (Giraldez
et al., 2002). Additional reports demonstrates that Hh in-
teractions with HS regulate its movement during develop-
ment (The et al., 1999) and that these interactions change
during early postnatal mouse development (Rubin et al.,
2002), suggesting that indeed other morphogens may be
subject to the same degree of regulation as FGF family
members. A critical question that remains is what affect
the developmental stage–specific changes in HS identified
in this paper have on the function of these signaling mole-
cules. It may be that these molecules are less sensitive to
changes in HS structure than FGFs such that subtle
changes in HS may have no effect on their activity. A
more intriguing possibility is that some or all of these pro-
teins are sensitive to such changes in HS, so that develop-
mental alterations in HS structure play a crucial role in
modulating the numerous cellular processes regulated by
these morphogens.
Materials and methods
Image acquisition and manipulation
All images were acquired at RT using Image-Pro® Plus version 1.3 from
a microscope (model Microphot-FX; Nikon) with an attached Photomet-
rics Image Point™ scientific cooled CCD video camera. mAb 3G10
binding was detected using Cy3-conjugated donkey anti–mouse second-
ary antibodies (Molecular Probes). Bound FRAP was recognized with Al-
exa 546–conjugated donkey anti–rabbit secondary antibodies (Molecu-
lar Probes). FGF1 was identified using Alexa 488–conjugated donkey
anti–goat secondary antibodies. All slides were mounted with a cover-
slip in the aqueous, nonfluorescing mounting medium, Immu-mount
(Thermo Shandon). Pictures for composite images (Figs. 2 and 3) were
obtained using a 6.3  Neofluar objective (Carl Zeiss MicroImaging,
Inc.) with an NA of 0.2. All other pictures (Figs. 4–7) were acquired with
a 10  Fluor objective (Nikon) with an NA of 0.5. Images were pro-
cessed (brightness, contrast, and color balance adjustments only) in
Adobe Photoshop version 7.0.
FRAP fusion proteins
Soluble FRAP fusion proteins consist of the extracellular three Ig-like loop
domains of either the IIIb or IIIc splice variants of FR2 or the IIIc splice vari-
ant of FR3 fused to the NH2 terminus of human placental-AP (FR2bAP,
FR2cAP, and FR3cAP, respectively; Ornitz et al., 1992). FRAP cDNAs
were provided by D. Ornitz (Washington University, St. Louis, MO). Purifi-
cation of FRAP fusion proteins has been described previously (Allen et al.,
2001; Rapraeger, 2002).
FGF ligands
The SG13009 strain of Escherichia coli transformed with the pQE16 ex-
pression plasmid containing the cDNA encoding murine FGF8b was the
gift of C. MacArthur (Washington University). Purification of bacterially ex-
pressed His-tagged FGF8b has been described previously (MacArthur et
al., 1995; Rapraeger, 2002). Because there have been reports of His-
tagged proteins binding nonspecifically to HS (Lacy and Sanderson, 2002),
experimental results with His-tagged FGF8b were confirmed using un-
tagged, commercially available recombinant human FGF8b (Peprotech).
Recombinant human FGF1 was the gift of B. Olwin (University of Colo-
rado at Boulder, Boulder, CO) or was obtained commercially (Intergen).
HAB binding assay
FRAP binding to FGF–heparin was performed using HABs (Bio-Rad Labora-
tories). FRAP was incubated in Hepes-buffered RPMI   10% CS   4 mM
L-glutamine at 100 nM with 10- l HABs in either the absence or the pres-
ence of 30 nM human recombinant FGF1 or 30 nM human recombinant
FGF8b for 1 h at RT on a rotator (Scientific Equipment Products). HABs bear-
ing FRAP were washed with either TBS or TBS containing 500 mM NaCl and
loaded into 96-well plates with an equal volume of AP substrate solution; AP
activity was determined by absorbance at 405 nm. Bound FRAP was calcu-
lated as a percentage of the total FRAP added to each treatment group.
LACE assay
LACE assays were performed as described previously (Friedl et al., 2001; Ra-
praeger, 2002). Embryos were harvested from timed pregnant CD-1 mice
(Charles River Laboratories) and frozen in optimal cutting temperature com-
pund (VWR International). Hs2st
    and Hs2st
 /  embryos were the gift of C.
Alexander (University of Wisconsin). Embryos were staged based on the cri-
teria of the Edinubrgh Mouse Atlas Project (http://genex.hgu.mrc.ac.uk/Data-
bases/Anatomy/MAstaging.html) and the work of Kaufman (1992). For E8.5
embryos, turning of the embryos occurred as the result of physical manipu-
lation during the embedding process. 5- m fresh frozen sections from E8.5,
E9.5, E12, or E18 embryos were obtained and prepared as described previ-
ously (Allen et al., 2001). For analysis of FRAP binding to endogenous HS,
frozen sections were incubated with 30 nM recombinant human FGF1 or
FGF8b and 100 nM FR2cAP or FR3cAP in Hb-RPMI containing 10%CS and
4 mM L-glutamine. Bound FRAP was identified by incubation with poly-
clonal rabbit anti-PLAP (Biomeda Corp.) for 30 min. FGF1 was detected us-
ing a goat anti-FGF1 antibody (R&D Systems).
Heparin competition experiments
To examine heparin or chemically desulfated heparin competition of FRAP
binding, tissue sections were preincubated for 1 h with 30 nM FGF, fol-
lowed by triplicate washes with TBS. 100 nM FRAP and 50 nM porcine
intestinal mucosa heparin (Sigma-Aldrich), 50 nM 2-ODS heparin
(Neoparin), or 50 nM 6-ODS heparin (Guimond et al., 1993) were incu-
bated together on the sections for 1 h at RT.
Cell culture
BaF3 lymphoid cells expressing FR2b, FR2c, and FR3c (FR2b7, FR2c2, and
FR31c cells, respectively) were provided by D. Ornitz. FR2b7, FR2c2, and
FR31c cells were cultured in RPMI 1640 (GIBCO BRL), 10% FCS (Hy-
clone), 10% WEHI-3–conditioned medium, 4 mM L-glutamine, 100 U/ml
penicillin, 100  g/ml streptomycin, and 0.0035%  -mercaptoethanol.
Wild-type CHO-K1 and mutant pgsF-17 cells were the gift of J. Esko
(University of California at San Diego, La Jolla, CA). Cells were grown in
Ham’s F-12 (GIBCO BRL), 10% FBS (Tissue Culture Biologicals), 4 mM
L-glutamine, 100 U/ml penicillin, and 100  g/ml streptomycin.
Cell binding experiments
CHO-K1 and pgsF-17 cells were plated at a density of 10
5 cells/well on
8-well TC chamber slides (Fisher) and allowed to adhere overnight. Cells
were fixed for 10 min in 4% PFA, followed by 2 M NaCl washes. Detec-
tion of FRAP binding was performed as described for the LACE assay.
Isolation of HS from CHO cells
CHO-K1 and pgsF-17 cells were grown to confluency in three T175 flasks
(Fisher Scientific). Cells were washed with TES (20 mM Tris, EDTA, and
165 mM NaCl) followed by incubation with 0.25% trypsin for 30 min at
37 C. The cell-trypsin mix was boiled for 30 min and the insoluble fraction
was pelleted by centrifugation at 1,500 g for 5 min. Protein was precipi-
tated with 6% TCA for 1 h at 0 C and pelleted by centrifugation at 10,000 g
for 20 min at 4 C. The supernatant was incubated with five volumes of
100% ethanol overnight at  20 C. Precipitated GAG was pelleted by cen-T
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trifugation at 10,000 g for 30 min at 4 C. The resulting pellet was resus-
pended in sterile water and the total amount of GAG was quantitated using
the Alcian blue method (Karlsson and Bjornsson, 2001).
BaF3 proliferation assays
FR2b7, FR2c2, and FR31c cells were added to 96-well flat bottom plates
(Fisher) at 10
5 cells/ml in IL-3–deficient media. 10 nM FGF was added
and incubated at 37 C for 48 h in the presence or absence of 100 nM
porcine intestinal mucosa heparin, 2-ODS heparin, 6-ODS heparin,
CHO-K1 HS, or pgsF-17 HS. After 48 h, CellTiter 96 AQueous One Solu-
tion reagent (Promega) was added to quantify relative cell numbers using
the manufacturer’s instructions.
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